Massivemarkets

DXCM

DexCom, Inc.

Nasdaq · usd

$79.54-1.53 (-1.89%)
As of 10:51:18 AM EST on Nov 10, 2026 · 15-minute delayed

DexCom, Inc. (DXCM) trades at $79.54 (-1.89%) as of 10:51:18 AM EST on Nov 10, 2026, -7.61% over the past month. Market cap is $30.24B, with 4.8 days to cover in short interest.

Stock performance

How DexCom, Inc. (DXCM) stock has performed from one day to one year, with its 52-week range.

-2.71%
-$2.22 over 1D
$79.55$80.19$80.83$81.487:00 AM9:35 AM10:00 AM10:25 AM10:50 AM$79.41
1D
-2.08%
1W
-4.32%
1M
-7.61%
YTD
+19.61%
1Y
+36.56%
52-wk range
$55.84 – $92.59

Key statistics

Today's trading snapshot for DXCM: day range, open, previous close, volume and market cap.

Day range
$79.38 – $81.07
Open
$80.88
Prev close
$81.07
Volume
438.09K
Market cap
$30.24B
Shares out
372.95M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for DexCom, Inc.: P/E, P/S, P/B, ROE and more.

P/E
29.88
P/S
5.80
P/B
11.68
P/FCF
26.97
ROE
39.1%
ROA
15.9%
Debt/Equity
0.49
Div yield
0.00%

As of Nov 6, 2026

8-K filings

Material corporate events DexCom, Inc. has disclosed to the SEC on Form 8-K.

  • On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock, par value $0.001 per share ("Common Stock"), with a repurchase period ending no later than December 31, 2027 (the "Share Repurchase Program").

  • Executive compensation changeSep 14, 2026

    In connection with Mr. Sylvain's promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the "Offer Letter") providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company's Amended and Restated 2015 Equity Incentive Plan, to participate in the Company's Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.

  • Director appointmentSep 10, 2026

    “On September 10, 2026, the Board of Directors ... increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.” “The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation Committee and the Audit Committee of the Board, effective immediately.”

  • Annual meeting resultsMay 28, 2026

    On May 27, 2026, DexCom, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting")... Dexcom stockholders elected the following twelve nominees to the Company's board of directors... Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom's independent registered public accounting firm... Dexcom stockholders approved, on a non-binding advisory basis, the compensation of Dexcom's named executive officers.

  • On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than June 30, 2027. In connection with the approval of the Share Repurchase Program, the Board of Directors terminated its existing share repurchase program, of which $250.0 million remained available to be repurchased under the program.

Dividend history and stock splits

DexCom, Inc.'s recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 4-for-1Jun 13, 2022

DXCM short interest

How heavily DXCM is shorted: shares short, days to cover and average daily volume.

Days to cover
4.8
Short interest
15.69M
Avg volume
3.3M

As of · reported to FINRA twice monthly.

DXCM news

The latest news and headlines about DexCom, Inc. (DXCM).

Frequently asked questions

What is the DexCom, Inc. (DXCM) stock price today?

DexCom, Inc. (DXCM) is trading at $79.54 (-1.89% on the day) as of 10:51:18 AM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is DexCom, Inc.?

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet…

What is the short interest in DXCM?

As of Oct 15, 2026, DXCM has 15.69M shares short and 4.8 days to cover.

What exchange is DXCM listed on?

DexCom, Inc. (DXCM) trades on Nasdaq in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.

Build with AI

Build an analysis of DXCM with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a DXCM analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.